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Objectives: This study aimed to use patient-level data to provide up-to-date estimates of early 
invasive breast cancer care costs by stage in England, and explore to what extent these costs vary 
across patient age and geographic region.  
Methods: This study identified women aged 50 years and over diagnosed with early invasive 
breast cancer between 01 January 2014 and 31 December 2015 from linked cancer registration and 
routine hospital datasets generated from the usual care for all NHS trusts in England. Cost 
estimates were derived from hospital records in Hospital Episodes Statistics with additional 
chemotherapy and radiotherapy information from the national datasets. We fitted general linear 
regression models to analyse the cost data. The model that best fit the data was selected using the 
model selection criteria of Akaike information criterion (AIC).  
Results: 55,662 women with early invasive breast cancer in England were included. The 
generalised linear model with log-gamma distribution fitted the data best. The costs of breast 
cancer care for one year following diagnosis were strongly dependent on stage at diagnosis 
controlling for other covariates. The estimated average per-patient hospital-related costs were 
£5,167 at stage I, £7,613 at stage II, and £13,330 at stage IIIA. Costs decreased with increasing 
age (p<0.001) and varied across region (p<0.001), deprivation level (p<0.001), referral source 
(p<0.01), presence of comorbidities (p<0.001), and tumour receptor (ER/PR/HER2) status 
(p<0.001).  
Conclusions: In England, costs of breast cancer care increased with advancing stage of the 
disease at diagnosis. Breast cancer costs varied by age and geographic region. 
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HIGHLIGHTS 
• UK estimates of the costs of breast cancer care by stage at diagnosis are out-of-date and 
may strongly bias the results of recent appraisals of the cost-effectiveness of breast cancer 
screening programmes. 
• The linkage between different national datasets at individual patient level was not possible 
until recently. This study identified 55,662 women aged 50 years and over diagnosed with 
early invasive breast cancer in England. We used anonymised patient-level data from the 
English Cancer Registration services, linked to other national datasets to provide 
information on patient demographics, tumour characteristics, hospital admissions, and the 
use of chemotherapy and radiotherapy in both inpatient and outpatient settings.  
• This study provides up-to-date estimates of breast cancer care costs by stage at diagnosis 
in England. Costs of early breast cancer care for one year following diagnosis increased 
with advancing stage of the disease. Breast cancer costs varied by age and geographic 




Breast cancer is the most commonly diagnosed female cancer in the United Kingdom (UK) 1. As 
in other high-income countries, the number of women living with breast cancer in the UK is 
increasing due to rises in incidence rates 1, increases in the number of older women 2, improved 
survival 3 and as a result of earlier detection and treatment improvements. It has been clearly 
established that earlier diagnosis of breast cancer reduces mortality 4, but the costs of breast cancer 
care are not well understood 5.  
Stage at diagnosis is an important factor shaping breast cancer treatment pathways. Treatment for 
more advanced breast cancer is more intensive and invasive 6, and tends to be associated with 
greater resource utilisation 7. Costs of breast cancer care by stage at diagnosis are important in 
quantifying the gains from early detection. If early treatment lowers costs, this will help offset 
some costs of interventions that aim to achieve earlier diagnosis. Treatment costs by stage would 
also inform the cost-effectiveness of breast cancer screening programmes. 
Existing UK data on the costs of breast cancer care by stage at diagnosis were published over 20 
years ago and are out-of-date 8. Recent National Institute for Health and Care Excellence (NICE) 
appraisals on the cost-effectiveness of breast cancer treatment have relied on modelled 
assumptions 9. This may lead to biased estimates of the full cost as there are multi-modal 
treatments. The consequences of biased estimates are serious as, potentially, therapies may be 
incorrectly rejected or approved by NICE based on outdated costs. Up-to-date estimates of the 
costs of breast cancer care by stage are required.  
In addition, recent evidence has revealed a differential approach to breast cancer management for 
older patients in the UK 10, which may explain the poorer survival of older women in the UK 
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compared to other European countries 11. Moreover, little is known about the geographic variation 
in costs of breast cancer care across England. For example, significant variations in rates and types 
of immediate breast reconstruction procedures were observed among National Health Service 
(NHS) hospitals in England 12. The differences in costs across patient age and region need to be 
determined.  
In this study, we used patient-level data generated from the usual care for all NHS trusts in England 
to estimate the costs of primary breast cancer care incurred in the first year after diagnosis, by 
stage among women aged 50 years and over, diagnosed in England, and to explore to what extent 
breast cancer costs vary across different patient ages and regions. 
METHODS 
This study used data from the National Audit of Breast Cancer in Older Patients (NABCOP) 
project, a national clinical audit commissioned by the Healthcare Quality Improvement Partnership 
as part of its National Clinical Audit and Patient Outcomes Programme, using data generated from 
the usual care for all NHS trusts in England. The details of the national clinical audit were 
described elsewhere 13. In brief, the audit uses anonymised patient-level data from the English and 
Welsh Cancer Registration services, linked to other national datasets to provide information on 
hospital admissions and the use of chemotherapy and radiotherapy. The Office for National 
Statistics (ONS) Death Register provides information on date and cause of death.  
Population and data 
The study population was restricted to women aged 50 years and over with newly diagnosed early 
invasive breast cancer (stages I, II and IIIA), as defined by ICD code C50 and stage at diagnosis, 
over the two years between 01 January 2014 and 31 December 2015 and who were treated within 
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the NHS in England. The data was available up to 31 December 2016 so that no patients were 
censored. This study was limited to early invasive disease because the primary treatment of early 
invasive disease conforms to a limited number of options and is typically delivered within one 
year. The treatment patterns for women with stage IIIb, IIIc, and IV disease are much more varied, 
being influenced by where the cancer has spread to. The duration of care can also be variable, with 
patients having a sequence of treatments depending upon how the tumour responds. The available 
data in this study did not capture second-line treatments and were insufficient to produce reliable 
cost estimates for patients with advanced disease. 
The cancer registration dataset contained patient demographics including age at diagnosis, 
ethnicity, date of diagnosis, and geographic region (cancer alliance). The 19 cancer alliances were 
established by NHS England to deliver the national recommendations within the NHS Cancer 
Strategy and to drive local quality improvements 14. The alliances are listed under Figure 1. 
Tumour characteristics included pathologic stage at diagnosis, tumour grade, oestrogen receptor 
(ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor 2 
(HER2) status. ER, PR, and HER2 are breast cancer molecular markers that guide the selection of 
the most appropriate drug therapies and are individually recorded as positive, negative, or 
borderline. 
Hospital admissions were identified from the Hospital Episode Statistics (HES) data. This 
contained date of admission, date of discharge, method of admission, method of discharge, date of 
spell (a continuous period of care in hospital) start, date of spell end, procedures undertaken (using 
the Office of Population Censuses and Surveys (OPCS) Classification of Surgical Operations 
version 4 codes) 15, and Healthcare Resource Group (HRG) 16. The HES data were also used as 
the data source for regional deprivation measured as the Index of Multiple Deprivation (IMD) 17 
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and comorbidity burden. Patient IMD scores were grouped into regional quintiles of deprivation, 
from most (=1) to least deprived (=5). Charlson Comorbidity Index was derived from the diagnosis 
fields within HES, which measures the presence of additional medical conditions co-occurring 
with breast cancer 18.  
The use of chemotherapy and targeted therapy was identified from the Systematic Anti-Cancer 
Therapy (SACT) Dataset. The radiotherapy information was obtained from the National 
Radiotherapy Dataset (RTDS). 
All these datasets were linked via a pseudonymised patient ID, generated from patients’ NHS 
number, date of birth, sex and postcode by the National Cancer Registration and Analysis Service 
(NCRAS). 
Resource use and measurement 
The analysis was conducted from a payer/NHS perspective in line with the NICE recommendation 
19. We categorised resource use during the first year of breast cancer care into various aspects of 
the care pathway: 1) diagnosis (triple assessment in a single visit); 2) breast procedures (breast 
surgery (resection, reconstruction, and surgery for lymph node involvement), and hospital length 
of stay); 3) chemotherapy; 4) radiotherapy; 5) endocrine therapy; and 6) targeted therapy.  
Patients with suspected breast cancer are recommended to undergo a triple diagnostic assessment 
in a single initial hospital visit, including clinical assessment, imaging (ultrasound and/or 
mammogram), and tissue biopsy 9,20. We measured the use of these diagnostic interventions using 
dates of imaging and biopsy.  
The types of breast resection surgeries include breast conserving surgery (BCS, removal of a part 
of the breast containing the cancer), mastectomy (removal of all breast), and mastectomy with 
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reconstruction. Also, we measured whether or not the patients had lymph node involvement and 
axillary surgeries based on HES data. Axillary surgeries covered the activities of sentinel node 
biopsy and axillary lymph node dissection 9. A maximum length of stay is specified for each HRG 
code. Where the patient length of stay during a spell in hospital exceeded that point, we 
documented the excess hospital bed days recorded by the number of overnight admissions.  
Whether patients received chemotherapy, radiotherapy, or targeted therapy were reported in SACT 
and RTDS datasets. ER+/PR+ patients aged over 50 years are recommended to receive 
postmenopausal endocrine therapy as per NICE guidelines 21,22. However, information on 
endocrine therapy was not well captured in SACT. We assumed an aromatase inhibitor 
(anastrozole) was offered for these postmenopausal ER+/PR+ patients and the adherence to the 
aromatase inhibitor in the first year after diagnosis was 88.3% based on a meta-regression analyses 
of 17 studies 23.  
Cost estimation 
Healthcare Resource Groups (HRG) are groups of hospital admissions that have been judged to 
consume a similar level of resource 16. We used unit costs from NHS reference costs 24 to assign 
costs using breast procedure-driven and diagnosis-driven core HRGs for the continuous inpatient 
spell. Some patient care episodes may have associated high-cost care elements that will generate 
unbundled HRGs as additions to the core HRG, such as chemotherapy, radiotherapy, and other 
high-cost drugs. Only records clearly related to breast cancer care were retained.  
Excess hospital bed days are reimbursed at a daily cost based on the core spell HRG code, which 
distinguishes between elective (arranged in advance) and non-elective (not arranged in advance) 
admissions. As the unit costs of elective and non-elective excess bed days can be different in the 
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NHS reference costs 24, we applied the elective or non-elective excess hospital bed day adjustment 
to the estimated cost where the patient length of stay exceeded the maximum specified for a given 
HRG code using the information on admission method. 
We used OPCS procedure codes from SACT and RTDS datasets to assign HRG codes to estimate 
the costs of chemotherapy and radiotherapy. We obtained the drug cost from the British National 
Formulary (BNF) 25 to estimate the endocrine therapy costs. In addition, we obtained the annual 
trastuzumab cost per patient including administration of treatment and cardiac monitoring from 
the NICE costing report to estimate the targeted therapy costs for HER2+ patients 22. All costs 
were converted to 2016 values using the Hospital and Community Health Service Index 26. 
Cost analysis 
We first checked whether there was a large mass at zero or extreme values, and fitted generalised 
linear regression models to estimate the mean costs of primary breast cancer care up to one year 
after diagnosis for women in England. The model contained a number of explanatory variables to 
assess the relationship between cost and patient characteristics. Demographic variables included 
age at diagnosis, ethnicity, geographic regions, and IMD. Disease characteristics included disease 
stage, ER/PR/HER2 status, Charlson Comorbidity Index, and referral source (via screening or not). 
As the disease stage may have different effects on costs across regions in England, we added the 
interaction term of stage and region in the regression models. A modified RESET procedure was 
used to test the functional form 27. 
Using a generalised linear model (GLM) enabled the cost estimates to handle common features of 
health care cost data, such as the substantial skewness with long right-hand tails 28, heteroskedastic 
errors and non-linear responses to covariates 29. Typically, a log-link function with a Gamma 
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distribution fitted health care costs well 28. However, there was no evidence that this was the 
dominant form of GLM in terms of model fit for cost data applications 30.  
In this study, we compared the models checking distributions of linear-normal, log-normal, and 
log-gamma respectively. Modified Park Test was conducted to guide the choice of distribution 
reflecting the relationship between variance and mean. The preferred model was selected as the 
one with the minimum Akaike information criterion (AIC) values. We reported the average 
marginal effects of explanatory variables on the total costs for the models to obtain the additional 
costs related to different characteristics. We predicted costs of primary breast cancer care by 
subgroups to obtain the average costs among patients at different age groups or disease stages. We 
conducted the complete case analysis using only data from patients for whom all variables 
involved in the analysis were observed. All statistical analyses were undertaken in STATA, version 
15.1. 
RESULTS 
The study included 55,662 women aged 50 years and over diagnosed with early invasive breast 
cancer in England between January 2014 and December 2015. The characteristics of the women 
by stage at diagnosis are presented in Table 1. The mean age was 67 years. The percentages of 
breast cancer patients diagnosed at stage I, stage II, and stage IIIA were 51%, 44%, and 6% 
respectively. 40% of breast cancer patients were screen-detected (found on mammography 
undertaken by the NHS National Breast Cancer Screening Programme), while the other 60% were 
referred from GP or other specialities, or detected due to an emergency presentation (<1%). 3% of 
patients in this study died within one year after diagnosis.  
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The resource use of breast cancer care is shown in Table 2. Determining whether a woman had 
triple diagnostic assessment was not straightforward because many imaging and biopsy dates were 
incomplete in the datasets 13. Adopting a strict set of criteria for the analysis of English data 
suggested that among women diagnosed with early invasive breast cancer, and who were not 
referred from screening, 28% received triple assessment in a single visit. If the criteria were relaxed 
(assuming missing mammogram/biopsy dates were the same as the date of biopsy/mammogram 
respectively, incorporating the use of ultrasound where no mammogram was recorded, and 
allowing dates of biopsy and mammogram to differ by one day), the estimated proportion of 
women having a triple diagnostic assessment on the same day was 82%. The rates of mastectomy, 
mastectomy with reconstruction, and axillary lymph node dissection increased with more 
advanced cancer stage at diagnosis, while the rates of BCS and sentinel node biopsy decreased 
with advancing stage. The time spent in hospital was short for most breast cancer patients. Most 
women were typically admitted and discharged as day cases, and the excess hospital bed days per 
patient were 0.06 days showing increasing trend by advanced stage. In addition, the proportion of 
patients receiving chemotherapy or targeted therapy at stage IIIA was higher than stage I or II. The 
proportion receiving radiotherapy among patients having BCS was 88% compared to 41% for 
patients having mastectomy.  
The crude costs of breast cancer care among 55,662 patients increased with more advanced disease, 
with very few (<3%) patients having zero costs and no extreme values (all values below £100,000). 
The subcategories of diagnosis and procedure costs, chemotherapy costs, radiotherapy costs, and 
targeted therapy costs all rose with higher stage (Appendix 1). There was some variation in the 
crude costs of primary breast cancer care across cancer alliances, with overall costs typically 
falling between £5,500 and £7,000 and the highest cost of  £8,549 incurred in South East London 
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(Figure 1). The variation in total costs of breast cancer care across cancer alliances was driven by 
all component costs according to one-way analysis of variance (ANOVA) results.  
The results of the compared regression models are shown in Table 3, using data from 22,325  
patients for whom all variables involved in the analysis were observed. The modified RESET 
procedure supported the functional form of the model. Missing data in HES was negligible with 
the exception of Charlson Comorbidity Index (3%) while the level of incompleteness in Cancer 
Registry was larger with PR status (51%), HER2 status (17%), ER status (14%), and ethnicity 
(6%). The Modified Park Test indicated the choice of a gamma distribution and the GLM with 
log-gamma distribution reported the minimum AIC. The regression model showed that even 
controlling for other cancer characteristics the total cost of primary breast cancer care increased 
with advancing stage at diagnosis. Patients diagnosed at stage II incurred £1,912 (S.E. £72) more 
costs and patient at stage IIIA incurred £6,415 (S.E. £253) more costs compared to those diagnosed 
at stage I (p<0.001). 
The regression model indicated that breast cancer costs decreased with increasing age (p<0.001), 
more comorbidities (p<0.001) and higher levels of deprivation (p<0.001). Patients with screen-
detected cancers incurred lower costs than those diagnosed outside screening (p<0.01). There was 
strong evidence of lower costs in ER/PR+ patients and higher costs in HER2+ patients (p<0.001). 
There was also evidence that the costs of primary breast cancer care varied across regions in 
England (p<0.001). The average marginal effects are presented in Table 3 and Appendix 2.  
We have reported the average predicted total costs of primary breast cancer care within one year 
after diagnosis using a GLM regression controlling for patient demographics and tumour 
characteristics. The costs of breast cancer care within one year after diagnosis was predicted to be 
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£6,774 (S.E. £32) for all stages, with £5,167 (S.E. £27) at stage I, £7,613 (S.E. £48) at stage II, 
and £13,330 (S.E. £213) at stage IIIA (Figure 2). The predicted costs of primary breast cancer care 
were £8,782 (S.E. £68) for patients aged 50-59 years, £7,062 (S.E. £50) for 60-69 years, £5,925 
(S.E. £51) for 70-79 years, £3,459 (S.E. £42) for 80-89 years, and £1,266 (S.E. £39) for over 90 
years respectively (Figure 3). 
DISCUSSION  
The principle aim of this study was to generate up-to-date estimates of initial early invasive breast 
cancer care costs by stage at diagnosis in England, controlling for patient demographics and 
tumour characteristics. Our results show that the costs of early breast cancer care for the first year 
after diagnosis increase with more advanced stage at diagnosis. The care costs of stage IIIA disease 
are more than double those of stage I disease. The finding is consistent with a global systematic 
review indicating increased breast cancer care costs with advanced stage, in which the treatment 
costs of breast cancer at stage II and stage III were reported to be 32% and 95% higher than stage 
I on average worldwide 5. Previous studies of the treatment costs of breast cancer by stage at 
diagnosis were rather limited due to the poor availability of staging information and were 
predominantly from the US 5. Before our analysis, there was only one very dated UK study 
estimating the costs of breast cancer care using patient-level data, reporting that the four-year costs 
of breast cancer were £6,039 at stage I, £6,749 at stage II, and £6,614 at stage III (converted to 
2016 values) 8. Our study has therefore provided important updated evidence on primary treatment 
costs for breast cancer by stage in England. This is important for future comparative assessment 
of the cost-effectiveness of breast cancer screening and therapy interventions.  
Compared to younger breast cancer patients, older patients were shown to incur lower costs. This 
is consistent with the studies that found older patients received fewer treatments in the UK. The 
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different patterns of resource utilisation might be a reason why the survival of older breast cancer 
patients in the UK and Ireland has been reported to be lower compared to other European countries 
11. Nonetheless, differences in the patterns of care among younger and older patients may arise for 
various reasons, including unmeasured differences in the disease, differences in the prevalence and 
severity of comorbidities and frailty that may contraindicate breast cancer treatments (e.g. surgery, 
chemotherapy or radiotherapy), differences in patient preferences and cultural attitudes, and less-
involvement of older patients in the decision making process 13.  
This study shows that patients with higher comorbidities incurred lower costs of breast cancer care 
for the first year after diagnosis. This is probably because patients with major comorbid conditions 
were more frail and had poorer ability to tolerate intensive breast cancer therapies. For example, 
significant comorbidity precludes surgery9 and platinum-based chemotherapy is often considered 
to be suitable only for fit patients with no significant comorbidities31.  
HER2 status is a major cost driver of breast cancer care in the first year after diagnosis in addition 
to the stage at diagnosis. Breast cancer patients with positive HER2 are eligible for targeted therapy 
with trastuzumab 21,32. The trastuzumab cost per patient including administration of treatment and 
cardiac monitoring is £15,080 based on NICE costing report 22, which makes HER2 status a 
leading driver of the costs of breast cancer care in the first year after diagnosis among patients with 
early invasive breast cancer.  
We further observed that the costs of breast cancer care varied across regions in England, after 
taking the differences in stage distributions across regions into consideration. This is of concern 
because it suggests different utilisation of breast cancer care across England. In the UK, hospitals 
receive payment based on the procedure types according to the NHS National Tariff Payment 
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System 33. The tariffs are defined nationally and aligned to promote efficient and high-quality care 
but the actual cost of performing certain procedures can exceed the income that hospitals receive 
12. The potential for a financial loss may impact on the provision of different treatment options in 
hospitals and therefore be reflected by the total costs of breast cancer care across cancer alliances 
in England. An examination of costs could highlight areas for review locally and there would 
probably be a benefit in having benchmark costs for particular patient groups for regional audit. In 
addition to financial considerations, future research could also examine whether the regional 
variation in costs of breast cancer care is related to service provision and/or capacity barriers.  
The advantages of our study population are: (i) it includes all patients with a registered diagnosis 
of early invasive breast cancer in England, diagnosed and treated in an NHS trust, (ii) individual 
patient-based information is available on a large number of variables such as socio-demographic 
factors, comorbidities, and referral source; (iii) information on tumour characteristics and 
treatment received is included; (iv) linkage between multiple national databases allows more 
comprehensive analysis.  
Our study is subject to some limitations. We only included breast cancer patients aged 50 years 
and over, and limited the follow-up period to one year following diagnosis. However, some 
treatments for early invasive breast cancer are likely to fall outside the one-year period, such as 
endocrine therapy and HER2 therapy. Also, we excluded patients with metastatic breast cancer 
and did not consider the costs of recurrence. This will underestimate the overall cost of care 
throughout the entire patient pathway. Costs of care in the context of higher stage disease are likely 
to be disproportionately underestimated given the higher risk of recurrence. Also some costs are 
not captured in this study relating to managing side effects, GP visits, etc. Although stage and 
receptor status are included in the analysis, some other tumour characteristics are not considered 
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such as the influence of multicentricity and the presence of ductal carcinoma in situ (DCIS) with 
the invasive cancer. Moreover, using the standard errors of the average predicted costs by stage in 
an economic evaluation requires careful consideration. Patient and tumour characteristics were 
assumed to be fixed within each stage subgroup when costs were predicted. As the distribution of 
characteristics in each subgroup also has some uncertainty, the true uncertainty of the average 
costs by stage might be underestimated. In addition this study used data that were available up to 
31 December 2016. Some newly approved drugs after 2016 were not captured in this analysis. 
We have identified the key methodological differences in cost analysis in the previously published 
global systematic review comparing treatment costs of breast cancer by stage across countries 5. 
As no single regression model is dominant in costing analyses, we explored different regression 
models to deal with the skewness issue. In this study, we compared regression models with 
different distributions (linear-normal, log-normal, and log-gamma). Based on the model selection 
criteria, we evidenced that the GLM with a log-gamma distribution fit the data best.  
Moreover, there are many missing data in the imaging and biopsy dates due to the incomplete 
reporting of data. We adopted the relaxed criteria as described and assumed 82% of patients had a 
triple diagnostic assessment on the same day. To enable a better understanding of triple diagnostic 
assessment for breast cancer patients, data completion on imaging and biopsy dates needs to be 
improved. In this study, we conducted complete case analysis using only data from 22,537 patients 
for whom all variables involved in the analysis were observed. Missing data in HES was negligible 
with the exception of Charlson Comorbidity Index (3%) while the level of incompleteness in 
Cancer Registry was larger with PR status (51%), HER2 status (17%), ER status (14%), and 
ethnicity (6%). In further research, one could use multiple imputation for missing data 34.  
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In conclusion, this study provides up-to-date estimates of initial breast cancer care costs by stage 
at diagnosis in England. Costs of early invasive (stage I, II and IIIA) breast cancer care up to one 
year after diagnosis increased with advancing stage of the disease at diagnosis. Breast cancer costs 
varied by age and geographic region in England. 
ETHICS APPROVAL 
The study is exempt from UK National Research Ethics Committee approval as it involved 
secondary analysis of an existing dataset of anonymised data. The NABCOP has approval for 
processing health care information under Section 251 (reference number: 16/CAG/0079) for all 
NHS patients aged 50 years and over diagnosed with breast cancer in England and Wales. Also 
this analysis has received ethics approval from the London School of Hygiene & Tropical 
Medicine Ethics Committee (reference number 16184).  
ROLE OF THE FUNDING SOURCE 
This study was undertaken as part of the work by the National Audit of Breast Cancer in Older 
Patients (NABCOP). The Audit is commissioned by the Healthcare Quality Improvement 
Partnership (HQIP) as part of the National Clinical Audit and Patient Outcomes Programme, and 
funded by NHS England and the Welsh Government (www.hqip.org.uk/national-programmes). 
Neither the commissioner nor the funders had any involvement in the study design; in the 
collection, analysis, and interpretation of data; in the writing of the report; or in the decision to 
submit the article for publication. The authors had full independence from the HQIP. The aim of 
the NABCOP is to evaluate the care of older women with breast cancer in England and Wales, and 
support NHS providers to improve the quality of hospital care for these women. 
 19 
TABLES 
Table 1 Cohort characteristics by stage at diagnosis  
Variables  All  
(n=55,662) 






Age (years) Mean (sd) 67 (11) 66 (10) 69 (12) 66 (11) 
 50-59 years 15,766 (28%) 8,227 (29%) 6,492 (27%) 1,047 (34%) 
 60-69 years 18,698 (34%) 10,930 (39%) 6,897 (28%) 871 (28%) 
 70-79 years 12,441 (22%) 5,977 (21%) 5,760 (24%) 704 (23%) 
 80-89 years 7,294 (13%) 2,665 (9%) 4,229 (17%) 400 (13%) 
 90+ years 1,463 (3%) 433 (2%) 980 (4%) 50 (2%) 
Ethnicity White 49,175 (88%) 24,877 (88%) 21,559 (89%) 2,739 (89%) 
 Asian 1,364 (2%) 633 (2%) 633 (3%) 98 (3%) 
 Black 766 (1%) 304 (1%) 398 (2%) 64 (2%) 
 Other 862 (2%) 444 (2%) 367 (2%) 51 (2%) 
 Unknown 3,495 (6%) 1,974 (7%) 1,401 (6%) 120 (4%) 
Charlson Comorbidity Index 0 46,078 (83%) 23,760 (84%) 19,698 (81%) 2,620 (85%) 
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 1 5,084 (9%) 2,477 (9%) 2,342 (10%) 265 (9%) 
 2 1,764 (3%) 772 (3%) 889 (4%) 103 (3%) 
 3+ 914 (2%) 392 (1%) 492 (2%) 30 (1%) 
 Unknown 1,822 (3%) 831 (3%) 937 (4%) 54 (2%) 
Index of Multiple Deprivation 1 (most deprived) 7,608 (14%) 3,674 (13%) 3,468 (14%) 466 (15%) 
 2 9,830 (18%) 4,871 (17%) 4,410 (18%) 549 (18%) 
 3 11,585 (21%) 5,945 (21%) 5,011 (21%) 629 (20%) 
 4 13,023 (23%) 6,725 (24%) 5,600 (23%) 698 (23%) 
 5 (least deprived) 13,616 (24%) 7,017 (25%) 5,869 (24%) 730 (24%) 
Tumour grade Low  9,463 (17%) 7,163 (25%) 2,170 (9%) 130 (4%) 
 Intermediate 30,152 (54%) 15,285 (54%) 13,300 (55%) 1,567 (51%) 
 High 14,885 (27%) 5,170 (18%) 8,393 (54%) 1,322 (43%) 
 Unknown 1,162 (2%) 614 (2%) 495 (2%) 53 (2%) 
ER status Positive 41,872 (75%) 22,109 (78%) 17,601 (72%) 2,162 (70%) 
 Negative 6,196 (11%) 2,379 (8%) 3,316 (14%) 501 (16%) 
 Borderline 22 (<1%) 9 (<1%) 12 (<1%) 1 (<1%) 
 21 
 Not performed/unknown 7,572 (14%) 3,735 (13%) 3,429 (14%) 408 (13%) 
PR status Positive 19,078 (34%) 10,114 (36%) 7,949 (33%) 1,015 (33%) 
 Negative 8,386 (15%) 3,515 (12%) 4,238 (17%) 633 (21%) 
 Borderline 58 (<1%) 29 (<1%) 27 (<1%) 2 (<1%) 
 Not performed/unknown 28,140 (51%) 14,574 (52%) 12,144 (50%) 1,422 (46%) 
HER2 status Positive 5,494 (10%) 2,144 (8%) 2,900 (12%) 450 (15%) 
 Negative 38,589 (69%) 20,320 (72%) 16,234 (67%) 2,035 (66%) 
 Borderline 2,296 (4%) 1,165 (4%) 988 (4%) 143 (5%) 
 Not performed/unknown 9,283 (17%) 4,603 (16%) 4,236 (17%) 444 (14%) 
Referral source Screen-detected 22,193 (40%) 15,512 (55%) 6,072 (25%) 609 (20%) 
 Not screen-detected 33,469 (60%) 12,720 (45%) 18,286 (75%) 2,463 (80%) 
Death within one year  Dead 1,506 (3%) 446 (2%) 942 (4%) 118 (4%) 
 Alive 54,156 (97%) 27,786 (98%) 23,416 (96%) 2,954 (96^) 
Sd: standard deviation 
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Table 2 Resource use – n (%) unless otherwise stated 
Resource use All (n=55,662) Stage I (n=28,232) Stage II (n=24,358) Stage IIIA (n=3,072) 
1. Diagnosis 
 
   
Breast ultrasound# 16,548 (30%) 7,394 (26%) 8,157 (33%) 997 (32%) 
Mammography# 21,518 (39%) 10,012 (35%) 10,154 (42%) 1,352 (44%) 
Biopsy# 43,523 (78%) 23,505 (83%) 17,998 (74%) 2,020 (66%) 
2. Breast procedures     
Breast conserving surgery (BCS) 35,718 (64%) 21,962 (78%) 12,753 (52%) 1,003 (33%) 
Mastectomy 12,585 (23%) 3,342 (12%) 7,411 (30%) 1,832 (60%) 
Mastectomy and reconstruction 2,627 (5%) 1,131 (4%) 1,294 (5%) 202 (7%) 
Axillary lymph node dissection 10,044 (18%) 835 (3%) 6,783 (28%) 2,426 (79%) 
Sentinel node biopsy 42,091 (76%) 24,462 (87%) 16,469 (68%) 1,160 (38%) 
Excess hospital bed days – mean (sd) 0.06 (1.24) 0.03 (0.77) 0.09 (1.55) 0.15 (1.81) 
3. Chemotherapy     
Chemotherapy received 9,498 (17%) 2,404 (9%) 5,731 (24%) 1,363 (44%) 
4. Radiotherapy     
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Radiotherapy received  37,336 (67%) 19,895 (70%) 14,888 (61%) 2,553 (83%) 
1) Radiotherapy received among patients 
having BCS 31,290 (88%) 19,181 (87%) 11,196 (88%) 913 (91%) 
2) Radiotherapy received among patients 
having mastectomy 5,098 (41%) 348 (10%) 3,170 (43%) 1,580 (86%) 
5. Endocrine therapy     
Endocrine therapy received† 37,157 (67%) 19,581 (69%) 15,639 (64%) 1,936 (63%) 
6. Targeted therapy     
Targeted therapy received 3,606 (6%) 1,250 (4%) 2,002 (8%) 354 (12%) 
#Data on imaging and biopsy dates were incomplete in the datasets. Adopting a strict set of criteria, 28% received triple assessment in 
a single visit. If we assumed missing mammogram/biopsy dates were the same as the date of biopsy/mammogram respectively, 
incorporated the use of ultrasound where mammogram was not reported, and allowed dates of biopsy and mammogram to differ by 
one day, the estimated proportion of women having a triple diagnostic assessment on the same day was 82%.   
†We assumed 88.3% ER+/PR+ breast cancer patients received endocrine therapy based on a meta-regression analyses of 17 studies 23.
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Table 3 Results for first-year total costs of breast cancer care comparing alternative models 
– average marginal effects (standard error) 
Variables Linear-Normal Log-Normal Log-Gamma 
Stage II 1883 (81)*** 1758 (70)*** 1912 (72)*** 
Stage IIIA 5859 (160)*** 4468 (130)*** 6415 (253)*** 
Age 60-69 years -985 (92)*** -761 (79)*** -1071 (100)*** 
Age 70-79 years -2484 (104)*** -2275 (88)*** -2338 (102)*** 
Age 80-89 years -5055 (135)*** -5110 (113)*** -4792 (97)*** 
Age 90+ years -6795 (275)*** -6918 (238)*** -6986 (95)*** 
Region *** *** *** 
Region × Stage *** *** *** 
AIC 447,464 446,456 430,636 
N 22,325 
The reference group is patients aged 50-59 years diagnosed at stage I from North East and Cumbria. 
We controlled for ethnicity, Charlson Comorbidity Index, Index of Multiple Deprivation, 
ER/PR/HER2 status, and referral source (presented in Appendix 2).  
We conducted the complete case analysis and the sample size was 22,325 patients for whom all 
variables involved in the analysis were observed. Missing data in HES was negligible with the 
exception of Charlson Comorbidity Index (3%) while the level of incompleteness in Cancer 





Figure 1 Crude costs of first-year primary breast cancer care by region 
Regions are numbered from 1 to 19 for (1) North East and Cumbria (6.2% of breast cancer patients 
diagnosed in this region), (2) Lancashire and South Cumbria (2.8%), (3) Greater Manchester 
(4.9%), (4) West Yorkshire (4.3%), (5) Humber, Coast and Vale (2.8%), (6) South Yorkshire, 
Bassetlaw, North Derby (3.2%), (7) Cheshire and Merseyside (5.1%), (8) West Midlands (10.7%), 
(9) East Midlands (7.2%), (10) East of England (11.7%), (11) Peninsula (3.9%), (12) Somerset, 
Wiltshire, Avon & Gloucestershire (5.4%), (13) Wessex (5.8%), (14) Thames Valley (4%), (15) 
Surrey and Sussex (6.3%), (16) Kent and Medway (3.7%), (17) West London (5.4%), (18) South 
East London (2.2%), and (19) North Central and East London (4.5%). The vertical lines at the top 
are 95% confidence intervals around the total costs. 
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Figure 2 Predicted population average costs of first-year primary breast cancer care by 
stage at diagnosis 
We predicted the first-year costs of breast cancer treatment by stage at diagnosis controlling for 
age group, ethnicity, Charlson Comorbidity Index, Index of Multiple Deprivation, tumour receptor 
(ER/PR/HER2) status, referral source, and regions. The predicted costs were £5,167 (S.E. £27) at 
stage I, £7,613 (S.E. £48) at stage II, and £13,330 (S.E. £213) at stage IIIA for the population 
average. The vertical lines at the top are 95% confidence intervals around the total costs. 
F-test showed p-value <0.001. 
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Figure 3 Predicted costs of first-year primary breast cancer care by age groups 
The predicted costs of primary breast cancer care were £8,782 (S.E. £68) for patients aged 50-59 
years, £7,062 (S.E. £50) for 60-69 years, £5,925 (S.E. £51) for 70-79 years, £3,459 (S.E. £42) for 
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